Vesselon is committed to saving lives and improving the quality of life for those suffering from terminal cancers and other serious diseases.
Our novel therapeutic immuno-oncology conjugates are protected in circulation and actively targeted to tumors using an FDA approved lipid microsphere drug as the backbone of a proprietary encapsulated drug and drug platform technology.
PIONEERING SOLUTIONS TO MEDICAL CHALLENGES
Protection in Circulation for Safer Drug Delivery
Targeting of Tumors without Changing the Drug
Tumor Biodistribution
Our technology allows a higher percentage of the injected dosage to penetrate into the tumor so that toxicity can be reduced and efficacy enhanced.
Cytokine Proteins
Monoclonal Antibodies
RNA and DNA
